Stock analysis, trade plans, and proprietary indicators by Trend Edge.
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, inc… Read full Trend Edge analysis →
| Current Price | $8.11 |
|---|---|
| Market Cap | $553M |
| Float | 16.2M |
| Shares Outstanding | 70.8M |
| Price/Sales (TTM) | 446.37 |
| Profit Margin | 24.67% |
| Operating Margin (TTM) | -382.12% |
| Revenue (TTM) | $1.2M |
| Dividend Rate | None |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | N/A | -$2.5M | N/A | -$2.5M |
| 2021 | N/A | $8.7M | N/A | $8.7M |
| 2022 | N/A | $3.8M | N/A | $3.8M |
| 2023 | $350,131 | $13,560 | $153,445 | $22,246 |
| 2024 | $510,360 | -$1.4M | $155,356 | -$1.3M |
| 2025 | $596,817 | -$8.3M | -$42,149 | -$8.1M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Sep 2024 | N/A | $2.2M |
| Dec 2024 | N/A | $417,791 |
| Mar 2025 | N/A | -$3.4M |
| Jun 2025 | N/A | -$2.2M |
| Insider Ownership | 80.1% |
|---|---|
| Institutional Ownership | 0.4% |
| Short Float | 0.1% |
| % of All Funds Holding | 0.14% |
| Number of Funds Holding | 12 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $4.15 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $0.00 | Medium-term trend |
| Weekly | 80-Week SMA | $0.00 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $0.00 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $0.00 | Near-term monthly trend |
| Monthly | 20-Month SMA | $0.00 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $0.00 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Volume shelf data not available.
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | N/A | N/A | N/A | N/A | N/A |
| 1 Day | N/A | N/A | N/A | N/A | N/A |
| 1 Week | N/A | N/A | N/A | N/A | N/A |
| 2 Weeks | N/A | N/A | N/A | N/A | N/A |
| 1 Month | N/A | N/A | N/A | N/A | N/A |
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
Institutional holder breakdown coming soon.
Total institutional ownership: 0.4%
Total insider ownership: 80.1%
Founder-led management: Ethan Shen (Chief Executive Officer and Chairman)
| Total Filings | 3 |
|---|---|
| Net Value | +$128,525.26 |
| Net Shares Change | 34,178 |
| % of Float | 0.2% |
| C-Suite Filings | 3 |
| Clusters Detected | 0 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Shen Ethan PhD | CEO | +$128,525.26 | 3 | 3 buy |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-09-16 | Shen Ethan PhD | CEO | +$48,895 | Transaction at $3.85, now +110.6% |
| 2026-09-10 | Shen Ethan PhD | CEO | +$12,183 | Transaction at $3.93, now +106.4% |
| 2026-09-08 | Shen Ethan PhD | CEO | +$67,447.26 | Transaction at $3.67, now +121.0% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for YD Bio Ltd (YDES) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for YDES on Trend Edge →